MARKER THERAPEUTICS, INC. Revenue from Contract with Customer, Including Assessed Tax
MARKER THERAPEUTICS, INC. (MRKR) reported Revenue from Contract with Customer, Including Assessed Tax of $751.69 thousand for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-15.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax · last filed 2026-05-15
- MARKER THERAPEUTICS, INC. revenue from contract with customer, including assessed tax for the quarter ending 2026-03-31 was $751.69K, a 115.32% increase year-over-year.
- MARKER THERAPEUTICS, INC. revenue from contract with customer, including assessed tax for the quarter ending 2025-12-31 was $1.10M, a 51.00% decline year-over-year.
- MARKER THERAPEUTICS, INC. revenue from contract with customer, including assessed tax for the quarter ending 2025-09-30 was $1.23M, a 35.99% decline year-over-year.
- MARKER THERAPEUTICS, INC. revenue from contract with customer, including assessed tax for the quarter ending 2025-06-30 was $861.18K, a 26.35% decline year-over-year.
- MARKER THERAPEUTICS, INC. revenue from contract with customer, including assessed tax for fiscal 2025 was $3.55M, a 46.19% decline from fiscal 2024.
- MARKER THERAPEUTICS, INC. revenue from contract with customer, including assessed tax for fiscal 2024 was $6.59M, a 99.06% increase from fiscal 2023.
- MARKER THERAPEUTICS, INC. revenue from contract with customer, including assessed tax for fiscal 2023 was $3.31M, a 5.76% decline from fiscal 2022.
- MARKER THERAPEUTICS, INC. revenue from contract with customer, including assessed tax for fiscal 2022 was $3.51M, a 182.96% increase from fiscal 2021.
| Period end | Revenue from Contract with Customer, Including Assessed Tax 3 month | Revenue from Contract with Customer, Including Assessed Tax 3 month as first filed | Revenue from Contract with Customer, Including Assessed Tax 6 month | Revenue from Contract with Customer, Including Assessed Tax 9 month | Revenue from Contract with Customer, Including Assessed Tax 9 month as first filed | Revenue from Contract with Customer, Including Assessed Tax 12 month | Revenue from Contract with Customer, Including Assessed Tax 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-03-31 | $751.69K 10-Q · filed 2026-05-15 | $1.86M derived: sum of 2 quarters · filed 2026-05-15 | $3.09M derived: sum of 3 quarters · filed 2026-05-15 | $3.95M derived: sum of 4 quarters · filed 2026-05-15 | |||
| 2025-12-31 | $1.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $2.34M derived: sum of 2 quarters · filed 2026-03-18 | $3.20M derived: sum of 3 quarters · filed 2026-03-18 | $3.55M 10-K · filed 2026-03-18 | |||
| 2025-09-30 | $1.23M 10-Q · filed 2025-11-13 | $2.09M derived: sum of 2 quarters · filed 2025-11-13 | $2.44M 10-Q · filed 2025-11-13 | $4.69M derived: sum of 4 quarters · filed 2026-05-15 | |||
| 2025-06-30 | $861.18K 10-Q · filed 2025-08-14 | $1.21M 10-Q · filed 2025-08-14 | $3.46M derived: sum of 3 quarters · filed 2026-05-15 | $5.39M derived: sum of 4 quarters · filed 2026-05-15 | |||
| 2025-03-31 | $349.10K 10-Q · filed 2026-05-15 | $2.60M derived: sum of 2 quarters · filed 2026-05-15 | $4.53M derived: sum of 3 quarters · filed 2026-05-15 | $5.70M derived: sum of 4 quarters · filed 2026-05-15 | |||
| 2024-12-31 | $2.25M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $4.18M derived: sum of 2 quarters · filed 2026-03-18 | $5.35M derived: sum of 3 quarters · filed 2026-03-18 | $6.59M 10-K · filed 2026-03-18 | |||
| 2024-09-30 | $1.93M 10-Q · filed 2025-11-13 | $3.10M derived: sum of 2 quarters · filed 2025-11-13 | $4.34M 10-Q · filed 2025-11-13 | $5.40M derived: sum of 4 quarters · filed 2025-11-13 | |||
| 2024-06-30 | $1.17M 10-Q · filed 2025-08-14 | $2.41M 10-Q · filed 2025-08-14 | $3.47M derived: sum of 3 quarters · filed 2025-08-14 | $3.73M derived: sum of 4 quarters · filed 2025-08-14 | |||
| 2024-03-31 | $1.24M 10-Q · filed 2025-05-15 | $2.30M derived: sum of 2 quarters · filed 2025-05-15 | $2.56M derived: sum of 3 quarters · filed 2025-05-15 | $3.32M derived: sum of 4 quarters · filed 2025-05-15 | |||
| 2023-12-31 | $1.06M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $1.31M derived: sum of 2 quarters · filed 2025-03-31 | $2.08M derived: sum of 3 quarters · filed 2025-03-31 | $3.31M 10-K · filed 2025-03-31 | |||
| 2023-09-30 | $257.61K 10-Q · filed 2024-11-14 | $1.02M derived: sum of 2 quarters · filed 2024-11-14 | $2.25M 10-Q · filed 2024-11-14 | $3.01M derived: sum of 4 quarters · filed 2024-11-14 | |||
| 2023-06-30 | $762.66K 10-Q · filed 2024-08-14 | $2.00M 10-Q · filed 2024-08-14 | $2.76M derived: sum of 3 quarters · filed 2024-08-14 | $3.76M derived: sum of 4 quarters · filed 2024-08-14 | |||
| 2023-03-31 | $1.23M 10-Q · filed 2024-05-15 | $4.73M 10-Q · filed 2023-05-15 | $1.99M derived: sum of 2 quarters · filed 2024-05-15 | $2.99M derived: sum of 3 quarters · filed 2024-05-15 | $3.78M derived: sum of 4 quarters · filed 2024-05-15 | ||
| 2022-12-31 | $759.14K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | $1.76M derived: sum of 2 quarters · filed 2024-03-26 | $2.55M derived: sum of 3 quarters · filed 2024-03-26 | $3.51M 10-K · filed 2024-03-26 | $9.01M 10-K · filed 2023-03-22 | ||
| 2022-09-30 | $999.57K 10-Q · filed 2023-11-09 | $3.95M 10-Q · filed 2022-11-10 | $1.79M derived: sum of 2 quarters · filed 2023-11-09 | $2.75M 10-Q · filed 2023-11-09 | $5.70M 10-Q · filed 2022-11-10 | ||
| 2022-06-30 | $790.51K 10-Q · filed 2023-08-14 | $1.75M 10-Q · filed 2023-08-14 | |||||
| 2022-03-31 | $964.32K 10-Q · filed 2023-05-15 | ||||||
| 2021-12-31 | $1.24M 10-K · filed 2023-03-22 | ||||||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $0.00 derived: sum of 2 quarters · filed 2022-03-17 | $466.79K derived: sum of 3 quarters · filed 2022-03-17 | $466.79K 10-K · filed 2022-03-17 | |||
| 2020-09-30 | $0.00 10-Q · filed 2020-11-09 | $466.79K derived: sum of 2 quarters · filed 2021-08-10 | $466.79K 10-Q · filed 2021-11-10 | ||||
| 2020-06-30 | $466.79K 10-Q · filed 2021-08-10 | $466.79K 10-Q · filed 2021-08-10 | |||||
| 2019-12-31 | $213.19K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09 | $213.19K derived: sum of 2 quarters · filed 2021-03-09 | $213.19K derived: sum of 3 quarters · filed 2021-03-09 | $213.19K 10-K · filed 2021-03-09 | |||
| 2019-09-30 | $0.00 10-Q · filed 2020-11-09 | $0.00 derived: sum of 2 quarters · filed 2020-11-09 | $0.00 10-Q · filed 2020-11-09 | ||||
| 2019-06-30 | $0.00 10-Q · filed 2020-08-10 | $0.00 10-Q · filed 2020-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |